Bristol-Myers Squibb Company
TGF BETA RECEPTOR ANTAGONISTS
Last updated:
Abstract:
The invention relates generally to compounds of formula (I) that modulate the activity of TGF.beta.R-1 and TGF.beta.R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and N disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
3 Jan 2018
Issue date:
7 Nov 2019